Letter from GWPharma

Medications
1

I wrote GWPharma asking about there product for schizophrenia this is the reply i got.

Thank you for your email enquiring about our schizophrenia research.

GW’s product candidate, an oral formulation of GWP42003 (cannabidiol (CBD)), has shown notable anti-psychotic effects in accepted pre-clinical models of schizophrenia and in September 2015, GW announced positive top line results from an exploratory Phase 2a placebo-controlled clinical trial of CBD in 88 patients with schizophrenia who had previously failed to respond adequately to first line anti-psychotic medications. Link: http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Positive%20Proof%20of%20Concept%20Data%20in%20Schizophrenia.aspx.

Schizophrenia still features in the pipeline and GW is evaluating appropriate next steps regarding product development in this area with future research likely focused on paediatric orphan neuropsychiatric indications. Please visit our website occasionally for updates, as this is where we post the latest news and developments relating to our research pipeline and products www.gwpharm.com.

Thank you for taking the time to contact GW.

Kind regards

GW Global Medical Information Team

2 Likes
2

Very interesting - thank you

3

Future research will focus on paediatrics only. I’m getting a bad feeling about the future of cbd meds from GW pharma.

Fortunately echo pharma are also developing it.

http://www.echo-pharma.com/en/products-and-pipeline/pipeline/schizophrenia/

Well done on taking the initiative to write to them.

4

what phase is that drug in?

5

Phase 1

http://adisinsight.springer.com/drugs/800043019

6

dang thatll be ages before it reaches market :frowning:

2 Likes